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Background: Blunt thoracic aortic injury treatment has evolved over the past decade particularly with 
respect to endovascular intervention options. We inv stigated the trends in blunt thoracic aortic injury 
management and outcomes over an 11-year span at the sole tertiary referral center in our state.  
 
Methods: We retrospectively reviewed all patients who presented to our institution with blunt traumatic 
aortic injury between 2007 and 2017. Baseline demographics including aortic injury grade, injury severity 
score, and abbreviated injury scale were collected. Outcomes were compared by type and timing of 
treatment, which included either nonoperative management, endovascular repair, or open surgical repair. 
Bivariate and multivariable analyses were performed to examine treatment group differences and factors 
associated with 30-day mortality. 
 
Results: In total, 229 patients were reviewed. The distribution of injury severity was:  Grade 1 (30%), 
Grade 2 (8%), Grade 3 (30%), Grade 4 (31%). Overall, 27% underwent endovascular repair, 29% open 
surgery, and 44% definitive nonoperative management. Over the study period, there was a dramatic 
decline in open surgery and a corresponding rise in endovascular treatment. 30-day mortality for the 
entire cohort was 22%. Mortality by treatment subgroup was 30% for nonoperative management, 8.2% 
for endovascular, and 21% for open surgery. Delaying e dovascular or open surgical treatment by at leas
24 hours after admission was associated with significa tly improved 30-day survival.  
 
Conclusions: Procedural intervention, whether endovascular or surgical, is associated with improved 
mortality compared to nonoperative treatment. Delayed intervention, particularly in high grade injuries, 
may allow for initial patient stabilization and improved outcomes.  
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Blunt thoracic aortic injury (BTAI) remains a devast ting condition often accompanied by 
multiple traumatic injuries and is associated with high mortality1. BTAI is often the result of sudden 
deceleration in motor vehicle accidents (MVA) and falls, with some estimates indicating that up to 80% 
of these patients die before reaching the hospital2-4. Although BTAI incidence is <1% in trauma patients, 
it is the second leading cause of death in this population7-9. Advances in endovascular therapy have 
expanded management options for BTAI, and excellent outcomes with thoracic endovascular aortic repair 
(TEVAR) have led some to question the utility of open aortic repair (OAR)10,11. Given the paucity of data 
in a rapidly evolving field, we sought to analyze how treatment and outcomes of BTAI have changed over
the past decade at a large tertiary referral and American College of Surgeons-verified Level 1 trauma 
center. 
 
PATIENTS AND METHODS 
The Institutional Review Board of Indiana University approved this study. All patients with BTAI 
who presented to our institution between January 2007 and December 2017 were reviewed. Patients were 
retrospectively identified, and data elements were extracted from prospective institutional trauma and
cardiac surgery registries. Patient medical records were individually reviewed. Aortic injury severity was 
categorized by the grading system introduced by Azizzadeh et al.: Grade 1 (intimal injury), Grade 2 
(intramural hematoma), Grade 3 (pseudoaneurysm), and Grade 4 (rupture)12. To characterize the overall 
severity of clinical status at presentation, we utilized intubation status, mechanism of injury, systolic 
blood pressure (SBP) on admission, injury severity score (ISS), and the abbreviated injury scale (AIS). 
Treatment strategy was categorized as either nonoperative management (NOM), TEVAR, or OAR.  
Timing of interventional procedure (TEVAR or OAR) was defined as either Early (<24 hours from time 








 We used descriptive statistics such as mean and frequency distribution to describe the study 
cohort. Bivariate analyses were done utilizing stratified analysis by treatment group. ANOVA and 
Pearson’s chi-square tests were employed to identify differences in characteristics across treatment 
groups. T-tests for continuous variables and chi-square tests for categorical variables were used to 
compare between those who were alive or dead at 30-days. In bivariate analyses of categorical variables 
with expected cell-count less than 5%, we used exact tests to examine any differences. Multivariable 
analyses using procedure type, age, gender, race, injury mechanism, and AIS-chest were done to examine 
their association with 30-day mortality. A sub-group analysis among those who underwent TEVAR or 
OAR was performed using timing of procedure in a multivariable model. Adjusted odds ratio from the 
multivariable logistic models were reported with 95% confidence intervals. All analyses were performed 




 A total of 229 patients with BTAI were identified in the 11-year study period. General 
characteristics of the cohort are in Table 1. Mean age was 46 years and the cohort was predominately 
white and male. The injury mechanism was MVA in nearly 80%. Mean ISS was 37.6±13.8 and mean 
Chest AIS was 4.5±0.5. At initial presentation, them an SBP was 122±32 mmHg and the majority of 
patients were not intubated. Chest computed tomography (CT) or CT angiography (CTA) were the most 
common imaging modalities used to diagnose BTAI. The overall distribution of injury grade was 30% 
Grade 1, 8% Grade 2, 30% Grade 3, and 31% Grade 4. Over the study period, there was a slight increase 
in the number of Grade 1-3 cases, but starting in 2011 there was a dramatic decline in the number of 
Grade 4 (Figure 1). 
Of the entire cohort, 44% received definitive NOM, 27% underwent TEVAR, and 29% 
underwent OAR. Frequency of treatment type also changed over the study period, with significant decline 




in OAR and concomitant increase in TEVAR starting i 2011 (Figure 2). Baseline demographics were 
similar across the three treatment groups. 30-day mortality for all patients combined was 22%.  
 
Nonoperative Management  
 Patients who underwent NOM as definitive treatment r ceived anti-hypertensive therapy to 
maintain strict BP control and blood product transfusion as necessary. 75% of all Grade 1, 68% of all 
Grade 2, 30% of all Grade 3, and 22% of all Grade 4 injuries were treated with NOM (Table 1). In 
general, the NOM group was older (mean age 49 years), had a marginally lower Chest AIS (4.4), and 
were more likely to be involved in single vehicle MVA than those in the TEVAR or OAR groups. Grade 
3 and 4 patients treated with definitive NOM were those too severely ill or clinically unstable to withs and 
an interventional procedure. Overall 30-day mortality for all NOM patients was 30%, the highest of any 
treatment subgroup. As expected, mortality depended primarily on injury grade, with higher grade 
associated with increased mortality:  8% for Grade 1, 15% for Grade 2, 48% for Grade 3, and 94% for 
Grade 4. The mean intensive care unit (ICU) and total hospital length of stay (LOS) for NOM was 7 and 
10 days, respectively.  
 Pulmonary events, which included respiratory failure, reintubation, and acute respiratory distress 
syndrome (ARDS), were the most common complications and occurred in 21% of NOM patients (Table 
2).  Infectious complications, including sepsis, intraabdominal abscess, pneumonia, empyema, wound 
infection, and peritonitis, were the second most comm n and occurred in 12.7% of NOM patients. These 
pulmonary and infectious complications affected mostly Mild Injury (Grades 1-2) patients. Cardiac arrest 
was the third most common complication and occurred in 9.8% of the group, primarily in those with 
Severe Injury (Grades 3-4). Long-term follow-up was available in a relatively small number of patients 
(Table 3); this data reflected follow-up with any physician within our health system, not necessarily w th 
our specific group. 
 
Endovascular Surgical Intervention  




 All patients received medical management for stabilizat on and BP control prior to undergoing 
TEVAR. All TEVAR procedures were performed in a hybrid operating room. Mean procedure duration, 
fluoroscopy time, and radiation dose were 130+80 minutes, 9.9+9.5 minutes, and 619.9+533.0 mGy, 
respectively. Procedural vascular access was obtained via the transfemoral route in all cases. The left 
subclavian artery ostium was covered in 36% of cases, and 16% underwent left carotid to subclavian 
bypass. Our criteria for performing carotid to subclavian bypass were:  a) presence of a patent left internal 
mammary artery to left anterior descending artery bypass graft; b) if the left vertebral artery was dominant 
or larger than the right vertebral artery on imaging; c) prior thoracic or abdominal aortic procedures with 
increased risk of spinal cord ischemia.  
The types of endografts utilized throughout the study included the Medtronic Talent (Medtronic 
plc, Dublin, Ireland), Cook Zenith TX2 and Zenith Alpha (Cook Medical LLC, Bloomington, Indiana, 
USA), Gore TAG and conformable TAG (W.L.Gore & Associates Inc, Flagstaff, Arizona, USA), Cordis 
PALMAZ XL (Cardinal Health, Santa Clara, California, USA), and Bolton RelayPlus (Bolton Medical 
Inc, Sunrise, Florida, USA). TEVAR patient outcomes by device manufacturer are displayed in Table 4.  
7.2% of all Grade 1, 26% of Grade 2, 42% of Grade 3, and 30% of Grade 4 patients underwent 
TEVAR. Within this cohort, 51% underwent Early TEVAR and 49% were Delayed. 30-day mortality for 
the Early and Delayed groups was 16% and 0%, respectively. There was no difference in mortality based 
upon type of endovascular stent or whether carotid-subclavian bypass was performed. The mean ICU and 
total hospital LOS for TEVAR patients was 13 and 19 days, respectively (Table 1).  
Pulmonary complications were the most common, occurring in 30% of TEVAR patients, 
followed by major infections (16%), cardiac arrest (6.5%), and deep vein thrombosis (6.5%) (Table 2). 
These complications occurred virtually exclusively in the Severe Injury (Grades 3-4) groups. There was 
one early re-intervention required due to proximal col apse of a Gore stent resulting in pseudo-coarctation 
on postoperative day 10. All patients had postoperativ  imaging prior to discharge and there were no early 
endoleaks. Long-term follow-up imaging was available in 36% of TEVAR patients at 1-year, 25% at 2-




years, 20% at 3-years, and 7% at 5-years. There wer no late endoleaks or aortic interventions in cases 
where follow-up data was available.   
 
Open Aortic Repair 
 OAR was performed in 17% of all Grade 1, 5.2% of Grade 2, 27% of Grade 3, and 46% of Grade 
4 injuries (Table 1). All patients received immediate medical management upon presentation before 
undergoing OAR. Operative details included a left thoracotomy approach with repair performed using an 
interposition prosthetic graft of appropriate length depending on extent of injury. Pre-operative lumbar 
spinal drains were not routinely placed. When feasible, intraoperative motor-evoked and somatosensory-
evoked potential monitoring were utilized. Full cardiopulmonary bypass support was utilized in 23% of 
cases, while left heart bypass was utilized in 53%. Mean total procedure, bypass, and cross-clamp (if 
applicable) times were 222+98.9 minutes, 98+79 minutes, and 56+47 minutes, respectively.  
71% of OAR patients underwent Early surgery, usually due to frank rupture necessitating 
emergency operation. Overall 30-day mortality was 21%, with the Delayed group having lower mortality 
(5%) than the Early group (28%).  There was no difference in mortality based upon bypass strategy, 
bypass duration, and extent of aortic replacement. Mean ICU and total hospital LOS for OAR patients 
was 11 and 16 days, respectively. 
 As with NOM and TEVAR, the most common complications were pulmonary in nature and 
occurred in 42% of the OAR group (Table 2). Major infections were the second most common (24%), 
followed by cardiac arrest (9%). All of these affected almost exclusively Grades 3-4. In patients where 
follow-up data was available (Table 3), there was one mortality after postoperative day 30:  death from 
cardiac arrest on postoperative day 109 after suffering multiple retroperitoneal abscesses and persistnt 
bile leak from a grade 4 liver laceration that had occurred at the time of initial injury.  
 
Patient Characteristics by Thirty-Day Mortality 




 The entire cohort was evaluated to determine whether there were any variables that might predict 
30-day survival. Older age, non-white race, higher ISS and AIS scores, lower admission BP, and 
intubation status were significantly associated with greater 30-day mortality while gender, injury 
mechanism, or blood product administration were not. As expected, Grade 4 had much higher mortality 
than others; Grade 4 patients who received NOM had a 130 times greater 30-day mortality risk than those 
who underwent TEVAR (p=0.012). Grade 1-3 patients who received NOM had a 7 times higher 30-day 
mortality risk than those who underwent TEVAR or OAR (Adj OR 6.97, CI 1.18-41.16, p=0.032). 
Delayed intervention with either TEVAR or OAR was associated with better 30-day survival than Early 
intervention (Adj OR 0.09, 95% CI 0.00-0.93, p= 0.043). 
 
COMMENT 
This study of BTAI represents one of the largest serie  of this rare but high-acuity diagnosis. 
Over the study period, our institution remained the primary referral center for major trauma and aortic 
pathology for the state of Indiana. We identified sveral notable findings. First, there was a shift over time 
in utilization of the different treatment options: before 2011, OAR was the most common strategy 
employed, but after 2011 there was a sharp decline in OAR with concomitant increase in TEVAR and 
NOM (Figure 1). Over the same period there was a corresponding decrease in Grade 4 incidence. . These 
changes coincide with the release of the 2011 Society of Vascular Surgery (SVS) clinical practice 
guidelines recommending TEVAR for Grade 2 to 48. Because there are more institutions in our state 
offering TEVAR than OAR, and because of the critical n ture of Grade 4 injury that makes inter-
institutional transfer a high-risk endeavor, it is possible that the Grade 4 patients that would have been 
transferred to our center prior to 2011 are instead increasingly being treated definitively with TEVAR at 
other institutions. 
Secondly, we find that NOM is a reasonable strategy for Mild Injury (Grades 1-2). The majority 
(75%) of our Grade 1 were treated with NOM, which mirrors the SVS and Eastern Association for the 
Surgery of Trauma (EAST) clinical practice guidelins. These guidelines also recommend TEVAR for 




Grade 2 to 4, which was based upon then-available data demonstrating NOM mortality of 46% (the least 
favorable of the three treatment modalities)8,13. However, in publishing these guidelines the SVS 
acknowledged that the quality of evidence for BTAI management was “very low”8. In our cohort, 68% of 
all Grade 2 received NOM with subsequent 30-day mortality of 15%. Despite the SVS and EAST 
guidelines recommending TEVAR, a number of studies have reported NOM as a viable treatment strategy 
for Grade 29,14,15,16. Dubose et al. analyzed nine Level 1 trauma centers and found that NOM in Grades 1 
and 2 had “very low” rates of aorta-related mortality15. Similarly, Sandhu and colleagues conducted a 16-
year retrospective analysis and proposed that Grade 2 can be successfully managed with NOM, while 
Spencer et al. compared NOM and TEVAR in patients wi h low grade BTAI and concluded that NOM is 
safe in Grade 2 injury9,16. Our practice is similar to these investigators, with the majority of Grades 1 and 
2 undergoing NOM with acceptable results. Other institutions may pursue TEVAR for these patients, and 
we acknowledge this is also a reasonable approach. Wit  conflicting published data on the question of 
optimal treatment for low grade BTAI, we believe further prospective study on this particular issue of 
patient and treatment selection will be greatly beneficial.  
In our series, Grades 3 and 4 underwent definitive repair by either TEVAR or OAR unless the 
patient was too critically ill to tolerate procedural intervention or the severity of injuries was such that any 
intervention would be futile. The most common comorbid injuries that prevented procedural intervention 
included massive intracranial injury, intraabdominal exsanguination, and severe lung injury. For the 
TEVAR and OAR groups, our results are similar to thse reported by others demonstrating superior 
outcomes with Delayed intervention. Marcaccio and associates reported a significantly lower mortality 
with Delayed intervention compared to Early (5.4% vs. 11.9%), and Estrera et al. also supported Delayed 
repair based on a 12-year analysis in which Delayed int rvention had a 2% mortality (versus 27% 
mortality with Early intervention)1,6. An American Association for the Surgery of Trauma study showed 
that between 1997 and 2007 there were two notable trends: 1) a significant decrease in overall BTAI 
mortality, and 2) a concomitant increase in the aver g  time interval between injury and treatment from 
16 hours in 1997 to 54 hours in 2007, which suggested that the mortality improvements could be partially 




attributable to delayed intervention18. Based on such results, the 2015 EAST guidelines recommended 
immediate NOM with a focus on aggressive BP control followed by Delayed repair3,8,17,19,20.  
Our data support this approach of immediate medical correction of major metabolic derangements 
and unstable physiology prior to TEVAR or OAR. The majority of TEVAR in our study was performed 
as a Delayed procedure. The majority of OAR were peformed prior to 2011 as Early interventions, but 
the few OAR after 2011 were Delayed interventions ad had corresponding improved survival. Currently, 
we recommend TEVAR instead of OAR unless one of the ollowing is present:  a) the aorta caliber is too
small to safely accept an endograft without significant oversizing; b) the patient is younger than 20 years 
old; c) the aortic injury is located in the arch betw en the left common carotid and subclavian artery. 
Grade 3 and 4 patients typically have other co-morbid injuries, and heparinization—even if only for a 
brief duration—during TEVAR certainly poses a risk for exacerbating other hemorrhagic trauma. Our 
practice is to discuss this risk with the appropriate specialists involved (e.g., neurosurgery), and if a 
multidisciplinary consensus is to treat the immediate life-threatening BTAI first, then we proceed with 
TEVAR with as short a duration of anticoagulation as feasible. We prefer to perform TEVAR in a hybrid 
room if available, but the procedure can certainly be performed in a regular operating room with portable 
fluoroscopy. 
The types of TEVAR endografts utilized varied over the study period. Some of this is attributed 
to the development of newer generation devices and also to the inventory of devices available at our 
institution, which is primarily affected by the hospital’s purchasing decisions that are beyond surgeons’ 
control. Nonetheless, we found no difference in outc mes by device manufacturer or by specific device. 
Based on our experience, we believe that no single device or manufacturer is clearly superior to others.  
One limitation of our study is inherent to its retrospective nature, which naturally reduces our 
ability to understand how treatments were selected and the rationale for performing Early versus Delayd 
intervention. Also, our study reports the experience of a single institution and therefore results may not be 
generalizable to others. An additional limitation is the low long-term follow-up rate. While we attempt 
follow-up in all our patients, we have found this to be difficult in the trauma population. Moreover, many 




of our patients are transferred from all regions of the state, and this further reduces patients’ willingness 
or ability to follow-up with our center. Lastly, since BTAI patients tend to be relatively young, future 
research should involve longer-term outcomes of TEVAR patients to better understand the durability of 
endovascular devices.  
 
Conclusion 
Growing experience with endovascular treatment options have significantly altered the 
management paradigm of BTAI. While TEVAR has become a first-line treatment option for most cases, 
institutions that treat BTAI patients must be facile in all management modalities including medical and
open surgical repair. Future investigative efforts should include multi-institutional efforts at delineating 
optimal treatment algorithms based on predictive clinical factors as well as long term studies to asses  




















1. Marcaccio CL, Dumas RP, Huang Y, Yang W, Wang GJ, Holena DN. Delayed endovascular aortic 
repair is associated with reduced in-hospital mortality in patients with blunt thoracic aortic injury. J 
Vasc Surg 2018;68:64-73. 
2. Mousa AY, Dombrovskiy VY, Haser PB, Graham AM, Vogel TR. Thoracic aortic trauma: outcomes 
and hospital resource utilization after endovascular and open repair. Vascular 2010;18:250-5. 
3. Trust MD, Teixeira PGR. Blunt Trauma of the Aorta, Current Guidelines. Cardiol Clin 2017;35:441-
451.  
4. Teixeira PG, Inaba K, Barmparas G, et al. Blunt thoracic aortic injuries: an autopsy study. J Trauma 
2001;1:197-202.  
 
5. Shackford SR, Dunne CE, Karmy-Jones R, et al. The evolution of care improves outcome in blunt 
thoracic aortic injury: A Western Trauma Association multicenter study. J Trauma Acute Care Surg 
2017;83:1006-1013.  
6. Estrera AL, Gochnour DC, Azizzadeh A, et al. Progress in the treatment of blunt thoracic aortic 
injury: 12-year single-institution experience. Ann Thorac Surg 2010;90:64-71. 
7. Agostinelli A, Carino D, Borrello B, et al. Blunt traumatic injury to the thoracic aorta treated with 
thoracic endovascular aortic repair: a single-centre 20-year experience. Interact Cardiovasc Thorac 
Surg 2019;28:17-22.  
8. Lee WA, Matsumura JS, Mitchell RS, et al. Endovascular repair of traumatic thoracic aortic injury: 
clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg 2011;53:187-92. 
9. Sandhu HK, Leonard SD, Perlick A, et al. Determinants and outcomes of nonoperative management 
for blunt traumatic aortic injuries. J Vasc Surg 2018;67:389-398. 
10. Grigorian A, Spencer D, Donayre C, et al. National Trends of Thoracic Endovascular Aortic Repair 
Versus Open Repair in Blunt Thoracic Aortic Injury. Ann Vasc Surg 2018;52:72-78. 




11. Demetriades D, Velmahos GC, Scalea TM, et al. Operativ  repair or endovascular stent graft in blunt 
traumatic thoracic aortic injuries: results of an American Association for the Surgery of Trauma 
Multicenter Study. J Trauma 2008;64:561-71.  
12. Azizzadeh A, Keyhani K, Miller CC 3rd, Coogan SM, Safi HJ, Estrera AL. Blunt traumatic aortic 
injury: initial experience with endovascular repair. J Vasc Surg 2009;49:1403-8. 
13. Murad MH, Rizvi AZ, Malgor R, et al. Comparative effectiveness of the treatments for thoracic aortic 
transection. J Vasc Surg 2011;53:193-199. 
14. de Mestral C, Dueck A, Sharma SS, et al. Evolution of the incidence, management, and mortality of 
blunt thoracic aortic injury: a population-based analysis. J Am Coll Surg 2013;216:1110-5. 
15. Dubose JJ, Azizzadeh A, Estrera AL, Safi HJ. Contemporary management of blunt aortic trauma. J 
Cardiovasc Surg 2015;56:751-62. 
16. Spencer SM, Safcsak K, Smith CP, Cheatham ML, Bhullar IS. Nonoperative management rather than 
endovascular repair may be safe for grade II blunt traumatic aortic injuries: An 11-year retrospective 
analysis. J Trauma Acute Care Surg 2018;84:133-138. 
17. Neschis DG, Scalea TM, Flinn WR, Griffith BP. Blunt aortic injury. N Engl J Med 2008;359:1708-
16.  
18. Demetriades D, Velmahos GC, Scalea TM, et al. Diagnosis and treatment of blunt thoracic aortic 
injuries: changing perspectives. J Trauma 2008;64:1415-9. 
19. Fox N, Schwartz D, Salazar JH, et al. Evaluation and management of blunt traumatic aortic injury: a 
practice management guideline from the Eastern Associati n for the Surgery of Trauma. J Trauma 
Nurs 2015;22:99-110. 
20. Karmy-Jones R, Ferrigno L, Teso D, Long WB 3rd, Shackford S. Endovascular repair compared with 
operative repair of traumatic rupture of the thoracic orta: a nonsystematic review and a plea for 
trauma-specific reporting guidelines. J Trauma 2011;7 : 059-72.  
 
 














Agea 45.8±19.7 years 45.4±15.7 40.6±20.0 49.5±19.7 0.0133 
Gender         0.525 
   Male 161(70.3) 42(68.9)  50(75.8) 69(67.7)  
   Female 68(29.7) 19(31.2) 16(24.2) 33(32.4)  
Race         0.952 
   White 182(79.5) 49(80.3)  52(78.8) 81(79.4)  
   Non-white  47(20.5) 12(19.7) 14(21.2) 21(20.6)  
SBPa 122±32 mmHg 121±26  125±35 121±33 0.6617 
Intubation status          0.148 
   Not intubated  215(93.9) 59(96.7)  63(95.5)  93(91.2)   
   Intubated  14(6.1) 2(3.3) 3(4.6) 9(8.8)  
Mechanism of injury         <0.0001 
   Fall 12(5.2) 4(6.6) 2(3.0) 6(5.9)  
   MVA— single  73(31.9) 20(32.8) 14(21.2) 39(38.2)  
   MVA —multiple  62(27.1) 20(32.8) 10(15.2) 32(31.4)  
   MVA —unspecified  54(23.6) 9(14.8) 33(50.0) 12(11.8)  
   Other 28(12.2) 8(13.1) 7(10.6) 13(12.8)   
Timing of procedure         <0.0001 
   Early 78(61.4) 31(39.7)  47(60.3) N/A  
   Delayed 49(38.6) 30(61.2) 19(38.8) N/A  
Imaging         0.035 
   CT  210(91.7)  60(98.4) 61(92.4) 89(87.3)  




   Other 19(8.3)   1(1.6)  5(7.6)  13(12.8)  
Injury grade         <0.0001 
   I 69(30.1) 5(8.2)  12(18.2) 52(51.0)  
   II  19(8.3) 5(8.2) 1(1.5) 13(12.8)  
   III  69(30.1) 29(47.5) 19(28.8) 21(20.6)  
   IV  72(31.4) 22(36.1) 34(51.5) 16(15.7)  
Blood products given         <0.0001 
   Yes 78(34.1) 32(52.5)    7(10.6) 39(38.2)  
   No 151(65.9) 29(47.5) 59(89.4)  63(61.8)  
ISSa  37.6±13.6 37.9±11.9 37.5±12.7 37.6±13.6 0.9778 
AISa          
   Chest 4.5±0.6 4.7±0.5 4.6±0.5 4.4±0.6 0.0026 
   Head, Neck 3.0±1.2 3.0±1.0 2.9±1.1  3.1±1.2 0.8543 
   Face 1.8±0.5 1.7±0.6  2.0±0.5  1.7±0.5 0.1966 
   Abdomen 2.9±1.0  2.8±0.8 3.2±1.1 2.9±1.1 0.1913 
   External 1.1±0.4 1.1±0.4 1.1±0.2 1.2 ±0.5 0.4075 
   Extremity 2.4±0.7  2.5±0.7  2.3±0.7 2.5±0.7 0.3527 
Hospital daysa 14.2±13.4 19.2±15.3 15.7±14.7 10.8±10.7 0.0003 
ICU daysa 10.2±0.4 13.1±10.2 11.3±12.1 7.0±8.4 0.0003 
Values are expressed as number(%) unless otherwise indicated. a, mean±standard deviation; AIS, 
abbreviated injury scale; CT, computed tomography; ICU, intensive care unit; ISS, injury severity score; 
MVA, motor vehicle accident; NOM, nonoperative management; OAR, open aortic repair; SBP, systolic 








Table 2. Complications by treatment type and injury severity 
 All Mild Injury 
(Grade 1 +Grade 2) 
Severe Injury 
(Grade 3 + Grade 4) 
NOM    
   Pulmonary  21(20.6) 15(71.4) 6(28.6) 
   Major infections  13(12.7) 10(76.9) 3(23.1) 
   Cardiac arrest 10(9.8) 1(10) 9(90) 
   Urinary tract infection 6(5.9) 5(83.3) 1(16.7) 
   Deep vein thrombosis 6(5.9) 4(66.7) 2(33.3) 
TEVAR    
   Pulmonary  18(29.5) 5(27.8) 13(72.2) 
   Major infections 10(16.4)  10(100) 
   Cardiac arrest  4(6.6)  4(100) 
   Deep vein thrombosis 





OAR    
   Pulmonary  28(42.4) 7(25) 21(75) 
   Major infections 16(24.2)  16(100) 
   Cardiac arrest  6(9.1) 1(16.7) 5(83.3) 
   Deep vein thrombosis 5(7.6)  5(100) 
   Urinary tract infection 2(3.0) 1(50) 1(50) 
























1 40(65.6) 36(54.5) 41(40.1) 
2 31(50.8) 30(45.5) 37(36.3) 
5 13(21.3) 23(34.8) 19(18.6) 











































Table 4. TEVAR patient volume and outcomes by year and by device manufacturer 
Year  TEVAR Device Manufacturer  
 Gore Cook Medtronic Cordis Bolton Total 
2007 - - - 1 - 1 
2008 7 - - - - 7 
2009 - - 6 - - 6 
2010 1 1 2 - - 4 
2011 1 1 - - - 2 
2012 4 1 - - - 5 
2013 8 - - - - 8 
2014 2 1 - - 1 4 
2015 8 2 2 - - 12 
2016 3 3 - - - 6 
2017 2 3 - - 1 6 
Total 36 12 10 1 1 61 
                     Mortality 
      
30-day 2 (5.6)a 1 (8.3)b 1 (10.0)c - - 4 
> 30-day - 1 (8.3)d - - - 1 
             Reintervention       
30-day 1 (2.8)e - - - - 1 
> 30-day - - - - - 0 
                    Endoleak 
      
30-day - - - - - 0 
> 30-day - - - - - 0 
Values are expressed as number(%) unless otherwise indicated. a, one mortality due to cardiac arrest, 
one due to brain death; b, mortality due to cardiac arrest; c, mortality due to brain death; d, mortali y 





due to respiratory failure on postoperative day 54;e, reintervention on postoperative day 10 due to 
collapse of proximal stent resulting in pseudocoarctation; >30-day results based only on patients with 

















































Figure 1. Year to year incidence of patients by injury severity. 
Figure 2. Blunt thoracic aortic injury treatment selection over time. NOM, nonoperative management; 
OAR, open aortic repair; TEVAR, thoracic endovascular aortic repair.  
 
 
 
 


